P3.02a-013 Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

P3.02a-013 Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial

Published:2017-01 Issue:1 Volume:12 Page:S1167-S1169
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Camidge D. Ross,Tiseo Marcello,Ahn Myung-Ju,Reckamp Karen,Hansen Karin,Kim Sang-We,Huber Rudolf,West Howard,Groen Harry,Hochmair Maximilian,Leighl Natasha,Gettinger Scott,Langer Corey,Paz-Ares Luis,Smit Egbert,Kim Edward,Reichmann William,Clackson Tim,Kerstein David,Haluska Frank,Kim Dong-Wan

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding the treatment response and resistance to targeted therapies in non-small cell lung cancer: clinical insights and perspectives;Frontiers in Oncology;2024-07-11

2. Development and Validation of Uv-Vis Spectroscopic Method for the Determination of Anticancer Drug Brigatinib;2023

3. Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2022-05

4. Emergence of ocular toxicities associated with novel anticancer therapeutics: What the oncologist needs to know;Cancer Treatment Reviews;2022-04

5. Targeted therapy for advanced anaplastic lymphoma kinase (ALK )-rearranged non-small cell lung cancer;Cochrane Database of Systematic Reviews;2022-01-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP